CEL-SCI (CVM) late Tuesday said it has closed on its best-efforts offering of more than 16.1 million common shares and prefunded warrants at $0.31 per share, generating $5 million in gross proceeds.
The cancer immunotherapy company plans to use the net proceeds to continue development of its Multikine injections, as well as working capital and other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.